🚨 JUST IN: $TBPH
Theravance completes $17/share cash-plus-CVR merger with Zymeworks; delists from Nasdaq

🚨 JUST IN: $TBPH
Theravance completes $17/share cash-plus-CVR merger with Zymeworks; delists from Nasdaq
🚨 JUST IN: $TBPH
Theravance discloses three shareholder lawsuits over Zymeworks merger, supplements proxy
#SEC #stocks #investing #TBPH #Litigation
🔗 secwatch.observer